WO2014096165A2 - Microvésicules remplies de gaz - Google Patents

Microvésicules remplies de gaz Download PDF

Info

Publication number
WO2014096165A2
WO2014096165A2 PCT/EP2013/077337 EP2013077337W WO2014096165A2 WO 2014096165 A2 WO2014096165 A2 WO 2014096165A2 EP 2013077337 W EP2013077337 W EP 2013077337W WO 2014096165 A2 WO2014096165 A2 WO 2014096165A2
Authority
WO
WIPO (PCT)
Prior art keywords
saturated
unsaturated fatty
fatty acid
acid
gas
Prior art date
Application number
PCT/EP2013/077337
Other languages
English (en)
Other versions
WO2014096165A3 (fr
Inventor
Anne LASSUS
Philippe Bussat
Thierry Bettinger
Original Assignee
Bracco Suisse Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bracco Suisse Sa filed Critical Bracco Suisse Sa
Priority to US14/653,793 priority Critical patent/US10010630B2/en
Priority to CN201380067383.8A priority patent/CN105026030B/zh
Priority to EP13821088.5A priority patent/EP2934740B1/fr
Priority to JP2015548564A priority patent/JP6313329B2/ja
Publication of WO2014096165A2 publication Critical patent/WO2014096165A2/fr
Publication of WO2014096165A3 publication Critical patent/WO2014096165A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes

Definitions

  • the invention relates to new gas-filled microvesicles, to their preparation and to their use in the diagnostic and therapeutic methods.
  • a class of contrast agents particularly useful for ultrasound contrast imaging, includes suspensions of gas bubbles of nano- and/or micro-metric size dispersed in an aqueous medium.
  • the gas is typically entrapped or encapsulated in a stabilizing film layer comprising, for instance, emulsifiers, oils, thickeners or sugars.
  • stabilizing film layer comprising, for instance, emulsifiers, oils, thickeners or sugars.
  • aqueous suspensions of gas-filled microvesicles where the bubbles of gas are bounded at the gas/liquid interface by a very thin envelope (film) involving a stabilizing amphiphilic material (typically a phospholipid) disposed at the gas to liquid interface.
  • a stabilizing amphiphilic material typically a phospholipid
  • These suspensions are advantageously prepared by contacting powdered amphiphilic materials, e.g. freeze-dried preformed liposomes or freeze-dried or spray-dried lipid solutions, with air or other gas and then with an aqueous carrier, while agitating to generate a suspension of gas-filled microvesicles which can then be administered, preferably shortly after its preparation.
  • aqueous suspension of gas-filled microvesicles and preparation thereof are disclosed, for instance, in US 5,271,928, US 5,445,813, US 5,413,774, US 5,556,610, 5,597,549, US 5,827,504, WO 97/29783 and WO2004/069284, which are herein incorporated by reference in their entirety.
  • the stabilizing layer may comprise, in addition to the above cited
  • Sonovue ® an ultrasound contrast agent commercialized by Bracco Canal S.A.
  • Sonovue ® comprises a mixture of phospholipids and fatty acid as the film-forming stabilizing layer.
  • microvesicles may be suitably modified, either for improving the diagnostic effect (e.g. through molecular imaging) and/or for therapeutic purposes, such as drug delivery and/or ultrasound mediated thrombolysis.
  • microvesicles may be associated (e.g. by inclusion in their boundary envelope) with therapeutic agents and/or with specific components which are capable to link to a determined target within a patient's body (known as "targeting ligands").
  • targeting ligands include, for instance, peptides, proteins, antibodies, aptamers or carbohydrates capable of binding to specific receptors expressed by organs or tissues during pathogenic processes such as, for instance, angiogenesis, inflammation or thrombus formation.
  • the Applicant has now found that it is possible to improve certain characteristics of phospholipid-based gas-filled microvesicles by including in the formulation of the stabilizing layer a mixture of saturated and unsaturated fatty acids.
  • a mixture of saturated/unsaturated fatty acids surprisingly increases the stability of the gas-filled microvesicle with respect to corresponding microvesicles containing only one of the respective saturated or unsaturated fatty acid in the formulation forming the stabilizing layer.
  • an aspect of the present invention relates to a suspension of gas- filled microvesicles in a physiologically acceptable liquid carrier, said microvesicles having a stabilizing envelope comprising a phospholipid, a saturated fatty acid and an unsaturated fatty acid, wherein the molar ratio between saturated and unsaturated fatty acid is from 2.5: 1 to 1 : 8.
  • the molar ratio between saturated and unsaturated fatty acids is from 1.5 : 1 to 1 : 7.5, more preferably from 1 : 1 to 1 : 6, even more preferably from 1 : 1.5 to 1 :4, particularly preferred being a molar ratio of from 1 : 2 to 1 : 3.
  • the molar ratio between phospholipids and the mixture of saturated/unsaturated fatty acids is from 3 : 7 to 4: 1, preferably from 2 : 3 to 7: 3 and even more preferably from 2.5 : 3 to 3 : 2.
  • said suspension is obtained by admixing a formulation (preferably in lyophilized form) comprising phospholipids and fatty acids in the above amounts with a physiologically acceptable liquid carrier in the presence of a
  • the formulation optionally further comprises pharmaceutically acceptable additives and/or excipients.
  • said formulation is in a freeze-dried (lyophilized) form.
  • the formulation of the invention comprising a mixture of saturated and
  • unsaturated fatty acids together with a phospholipid may be used for manufacturing gas-filled microvesicles useful in diagnostic imaging and/or as therapeutic agent.
  • the formulation of the invention is particularly useful for forming a layer which stabilizes the bubbles of gas (stabilizing layer) in a liquid suspension.
  • the formulation may comprise additional amphiphilic materials and is typically in the form of a freeze- dried (lyophilized) formulation, preferably comprising lyophilization additives.
  • the gas- filled microvesicles of the invention can be prepared by admixing said formulation with a physiologically acceptable liquid carrier in the presence of a physiologically acceptable gas.
  • fatty acids comprises within its meanings carboxylic acids comprising a relatively long aliphatic chain, e.g. from 10 to 28 carbon atoms (Ci 0 -C 2 8) -
  • the aliphatic chain is preferably a linear (straight) chain.
  • the fatty acids useful in a composition according to the invention preferably comprise a Ci 0 -C 2 4, aliphatic chain, more preferably C14-C 22 and even more preferably a Ci 6 -C 2 o aliphatic chain terminated by a carboxylic group.
  • Fatty acids can be either saturated or unsaturated (i.e. containing one or more unsaturations, typically a double bond).
  • Saturated fatty acids comprise fatty acids with no unsaturations in the aliphatic chain such as, for instance: capric (n-decanoic), lauric (n-dodecanoic), myristic (n- tetradecanoic), palmitic (n-hexadecanoic), stearic (n-octadecanoic), arachidic (n- eicosanoic), behenic (n-docosanoic) and n-tetracosanoic acid.
  • Preferred saturated fatty acids are myristic, palmitic, stearic and arachidic acid.
  • Unsaturated fatty acids may comprise one, two, three, four or five unsaturations (double bonds in particular) in the aliphatic chain.
  • the unsaturations are in the cis- configuration.
  • the unsaturated fatty acid comprises three or less unsaturations, more preferably two or less unsaturations; particularly preferred are unsaturated fatty acids comprising a single unsaturation in the aliphatic chain.
  • unsaturated fatty acids is sometimes indicated in the following with the number of carbons of the alkyl chain and the position of the unsaturation in the chain; for instance palmitoleic acid, i.e.
  • cis-9-hexadecenoic acid is referred to as C 16 , cis- ⁇ 9 (or briefly : C 16 , ⁇ 9 ).
  • unsaturated fatty acids comprise, for instance, decenoic, dodecenoic, tetradecenoic, hexadecenoic, hexadecadienoic, octadecenoic, octadecadienoic, octadecatrienoic, octadecatetraenoic, eicosenoic, eicosadienoic, eicosatrienoic, eicosatetraenoic, eicosapentaenoic, docosaenoic, docosadienoic, docosatrienoic, docosatetraenoic, docosapentaenoic and tetracosenoic acid .
  • Preferred unsaturated fatty acids comprise myristoleic (cis-9-tetradecenoic), palmitoleic (cis-9- hexadecenoic), sapienic (cis-6-hexadecenoic), oleic (cis-9-octadecenoic), linoleic (cis- 9, 12-octadecadienoic), linolenic (cis-9, 12, 15-octadecatrienoic), gondoic (cis- 11- eicosenoic), cis- l l, 14-eicosadienoic, cis-5,8, l l-eicosatrienoic, cis-8, 11, 14- eicosatrienoic, cis-l l, 14, 17-eicosatrienoic, arachidonic (cis-8, 11, 14, 17- eicosatetraenoic) and erucic (cis- 13-docosen
  • the mixture of saturated and unsaturated fatty acids preferably comprises acids having a length of the alkyl chain differing by at most four carbon atoms; more preferably the saturated and unsaturated acids differ by at most two carbon atoms and even more preferably by at most one carbon atom in their respective chain's length; particularly preferred are mixtures comprising fatty saturated and unsaturated acids having the same length of the alkyl chain (e.g . palmitic/palmitoleic acids, stearic/oleic acids, arachidic/gondonic acids, etc.) .
  • the Applicant has observed that by using a composition comprising a molar ratio of saturated/unsaturated fatty acids of from 2.5 : 1 to 1 : 8 it is possible to prepare gas- filled microvesicles having an increased stability with respect to microvesicles where only the started or unsaturated fatty is employed in the same concentration.
  • the molar ratio between saturated and unsaturated fatty acids in the composition is from 1.5 : 1 to 1 : 7.5, more preferably from 1 : 1 to 1 : 6, even more preferably from 1 : 1.5 to 1 : 4, particularly preferred being a molar ratio of from 1 : 2 to 1 : 3.
  • phospholipid is intended to encompass amphiphilic compounds containing at least one phosphate group and at least one, preferably two, (C 12 -C 22 ) hydrocarbon chain, capable of forming a stabilizing film-layer (typically in the form of a mono-molecular layer) at the gas-water boundary interface in the final microbubbles suspension. Accordingly, these materials are also referred to in the art as “film-forming phospholipids”.
  • phospholipids includes naturally occurring, semisynthetic or synthetic products, which can be employed either singularly or as mixtures.
  • suitable phospholipids include esters of glycerol with one or preferably two (equal or different) residues of fatty acids and with phosphoric acid, wherein the phosphoric acid residue is in turn bound to a hydrophilic group such as, for instance, choline (phosphatidylcholines - PC), serine (phosphatidylserines - PS), glycerol (phosphatidylglycerols - PG), ethanolamine (phosphatidylethanolamines - PE), inositol (phosphatidylinositol).
  • Esters of phospholipids with only one residue of fatty acid are generally referred to in the art as the "lyso" forms of the phospholipid or
  • lysophospholipids Fatty acids residues present in the phospholipids are in general long chain aliphatic acids, typically containing from 12 to 24 carbon atoms, preferably from 14 to 22; the aliphatic chain may contain one or more unsaturations or is preferably completely saturated.
  • suitable fatty acids included in the phospholipids are, for instance, lauric acid, myristic acid, palmitic acid, stearic acid, arachidic acid, behenic acid, oleic acid, linoleic acid, and linolenic acid.
  • saturated fatty acids such as myristic acid, palmitic acid, stearic acid and arachidic acid are employed.
  • phospholipid examples include phosphatidic acids, i.e. the diesters of glycerol-phosphoric acid with fatty acids; sphingolipids such as sphingomyelins, i.e. those phosphatidylcholine analogs where the residue of glycerol diester with fatty acids is replaced by a ceramide chain; cardiolipins, i.e. the esters of 1,3- diphosphatidylglycerol with a fatty acid; glycolipids such as gangliosides GM 1 (or GM2) or cerebrosides; glucolipids; sulfatides and glycosphingolipids.
  • phosphatidic acids i.e. the diesters of glycerol-phosphoric acid with fatty acids
  • sphingolipids such as sphingomyelins, i.e. those phosphatidylcholine analogs where the residue of glycerol diester with fatty acids is
  • Examples of naturally occurring phospholipids are natural lecithins
  • PC phosphatidylcholine
  • Examples of semisynthetic phospholipids are the partially or fully hydrogenated derivatives of the naturally occurring lecithins.
  • Preferred phospholipids are fatty acids di-esters of phosphatidylcholine, ethylphosphatidylcholine, phosphatidylglycerol, phosphatidic acid, phosphatidylethanolamine, phosphatidylserine, phosphatidylinositol or of sphingomyelin.
  • phospholipids are, for instance, dilauroyl-phosphatidyl- choline (DLPC), dimyristoyl-phosphatidylcholine (DMPC), dipalmitoyl-phosphatidyl- choline (DPPC), diarachidoyl-phosphatidylcholine (DAPC), distearoyl-phosphatidyl- choline (DSPC), dioleoyl-phosphatidylcholine (DOPC), 1,2 Distearoyl-sn-glycero-3- ethylphosphocholine (Ethyl-DSPC), dipentadecanoyl-phosphatidylcholine (DPDPC), 1- myristoyl-2-palmitoyl-phosphatidylcholine (MPPC), l-palmitoyl-2-myristoyl- phosphatidylcholine (PMPC), l-palmitoyl-2-stearoyl-phosphatidylcholine (PS
  • DSSP distearoylsphingomyelin
  • DLPI dilauroyl-phosphatidylinositol
  • DAPI diarachidoylphosphatidylinositol
  • DMPI dimyristoylphosphatidylinositol
  • DPPI dipalmitoylphosphatidylinositol
  • DSPI distearoylphosphatidylinositol
  • DOPI dioleoyl- phosphatidylinositol
  • Suitable phospholipids further include phospholipids modified by linking a hydrophilic polymer, such as polyethyleneglycol (PEG) or polypropyleneglycol (PPG), thereto.
  • PEG polyethyleneglycol
  • PPG polypropyleneglycol
  • Preferred polymer-modified phospholipids include "pegylated phospholipids", i.e. phospholipids bound to a PEG polymer. Examples of pegylated phospholipids are pegylated phosphatidylethanolamines ("PE-PEGs" in brief) i.e.
  • phosphatidylethanolamines where the hydrophilic ethanolamine moiety is linked to a PEG molecule of variable molecular weight (e.g. from 300 to 20000 daltons, preferably from 500 to 5000 daltons), such as DPPE-PEG (or DSPE-PEG, DMPE-PEG, DAPE-PEG or DOPE-PEG).
  • DPPE-PEG2000 refers to DPPE having attached thereto a PEG polymer having a mean average molecular weight of about 2000.
  • Particularly preferred phospholipids are DAPC, DSPC, DPPC, DMPA, DPPA, DSPA,
  • Most preferred are DSPG, DSPS, DSPE, DSPC, DAPC and mixtures thereof.
  • Mixtures of phospholipids can also be used, such as, for instance, mixtures of DPPE and/or DSPE (including pegylated derivates), DPPC, DSPC and/or DAPC with DSPS, DPPS, DSPA, DPPA, DSPG, DPPG, Ethyl-DSPC and/or Ethyl-DPPC.
  • Phospholipids the molar ratio of phospholipids with respect to the total amount of saturated or unsaturated fatty acids is from 3 : 7 to 4: 1, preferably from 2 : 3 to 7 : 3 and even more preferably from 2.5 : 3 to 3 : 2.
  • Other amphiphilic materials are from 3 : 7 to 4: 1, preferably from 2 : 3 to 7 : 3 and even more preferably from 2.5 : 3 to 3 : 2.
  • composition forming the stabilizing layer of the gas-filled microvesicles may comprise further amphiphilic components which may also contribute to the formation of the stabilizing layer such as, for instance; lipids bearing polymers, such as chitin, hyaluronic acid, polyvinylpyrrolidone or polyethylene glycol (PEG), also referred as "pegylated lipids”; lipids bearing sulfonated mono- di-, oligo- or polysaccharides;
  • cholesterol, cholesterol sulfate or cholesterol hemisuccinate lipids with ether or ester-linked fatty acids
  • polymerized lipids diacetyl phosphate; dicetyl phosphate; ceramides; polyoxyethylene fatty acid esters (such as
  • polyoxyethylene fatty acid stearates polyoxyethylene fatty acid stearates
  • polyoxyethylene fatty alcohols polyoxyethylene fatty alcohol ethers, polyoxyethylated sorbitan fatty acid esters, glycerol polyethylene glycol ricinoleate, ethoxylated soybean sterols, ethoxylated castor oil or ethylene oxide (EO) and propylene oxide (PO) block copolymers
  • sterol aliphatic acid esters including, cholesterol butyrate, cholesterol iso-butyrate, cholesterol palmitate, cholesterol stearate, lanosterol acetate, ergosterol palmitate, or phytosterol n-butyrate
  • sterol esters of sugar acids including cholesterol glucuronides, lanosterol glucuronides, 7- dehydrocholesterol glucuronide, ergosterol glucuronide, cholesterol gluconate, lanosterol gluconate, or ergoste
  • DDAB dimethyldioctadecylammonium bromide
  • CAB hexadecyltrimethylammonium bromide
  • tertiary or quaternary ammonium salts comprising one or preferably two (C 1 0-C 2 0), preferably (Ci 4 -Ci 8 ), acyl chain linked to the N-atom through a (C 3 -C 6 ) alkylene bridge, such as, for instance, l,2-distearoyl-3-trimethylammonium-propane (DSTAP), l,2-dipalmitoyl-3-trimethylammonium-propane (DPTAP), l,2-oleoyl-3- trimethylammonium-propane (DOTAP), l,2-distearoyl-3-dimethylammonium-propane (DSDAP); and mixtures or combinations thereof.
  • DSTAP l,2-distearoyl-3-trimethylammonium-
  • amphiphilic compounds if present, may be present in variable amounts, for instance up to 25% by moles of the composition forming the stabilizing layer, preferably up to 10%.
  • a lyophilization additive such as an agent with cryo protective and/or lyoprotective effect and/or a bulking agent, for example an amino-acid such as glycine; a carbohydrate, e.g. a sugar such as sucrose, mannitol, maltose, trehalose, glucose, lactose or a cyclodextrin, or a polysaccharide such as dextran, chitosan and its derivatives (for example:
  • the amount of additive e.g. polyethylene glycol
  • the amount of additive may vary from about 90% to about 99.99% (by weight) of the total amount of the lyophilized preparation.
  • excipients or additives may be present either in the dry formulation for the preparation of the microbubbles or may be added together with the aqueous carrier used for the reconstitution thereof, without necessarily being involved (or only partially involved) in the formation of the stabilizing envelope of the microbubble.
  • excipients or additives include pH regulators, osmolality adjusters, viscosity enhancers, emulsifiers, bulking agents, etc. and may be used in conventional amounts. For instance compounds like
  • polyoxypropylene glycol and polyoxyethylene glycol as well as copolymers thereof can be used.
  • viscosity enhancers or stabilizers are compounds selected from linear and cross-linked poly- and oligo-saccharides, sugars and hydrophilic polymers such as polyethylene glycol.
  • compositions and microvesicles according to the invention may optionally comprise a targeting ligand.
  • targeting ligand includes within its meaning any compound, moiety or residue having, or being capable to promote, a targeting activity (e.g. including a selective binding) of the microvesicles of a composition of the invention towards any biological or pathological site within a living body.
  • Targets with which targeting ligand may be associated include tissues such as, for instance, myocardial tissue (including myocardial cells and cardiomyocytes), membranous tissues (including endothelium and epithelium), laminae, connective tissue (including interstitial tissue) or tumors; blood clots; and receptors such as, for instance, cell-surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments, and immunoglobulins and cytoplasmic receptors for steroid hormones.
  • tissues such as, for instance, myocardial tissue (including myocardial cells and cardiomyocytes), membranous tissues (including endothelium and epithelium), laminae, connective tissue (including interstitial tissue) or tumors; blood clots; and receptors such as, for instance, cell-surface receptors for peptide hormones, neurotransmitters, antigens, complement fragments, and immunoglobulins and cytoplasmic receptors for ste
  • the targeting ligand may be synthetic, semi-synthetic, or naturally-occurring.
  • Materials or substances which may serve as targeting ligands include, for example, but are not limited to proteins, including antibodies, antibody fragments, receptor molecules, receptor binding molecules, glycoproteins and lectins; peptides, including oligopeptides and polypeptides; peptidomimetics; saccharides, including mono and polysaccharides; vitamins; steroids, steroid analogs, hormones, cofactors, bioactive agents and genetic material, including nucleosides, nucleotides and polynucleotides.
  • the targeting ligand may be a compound per se which is admixed with the other components of the microvesicle or may be a compound which is bound to an
  • amphiphilic molecule typically a phospholipid employed for the formation of the microvesicle.
  • the targeting ligand may be bound to an
  • amphiphilic molecule e.g. a phospholipid
  • amphiphilic molecule forming the stabilizing envelope of the microvesicle through a covalent bond.
  • the specific reactive moiety that needs to be present on the amphiphilic molecule will depend on the particular targeting ligand to be coupled thereto.
  • suitable reactive moieties for the amphiphilic molecule may be isothiocyanate groups (that will form a thiourea bond), reactive esters (to form an amide bond), aldehyde groups (for the formation of an imine bond to be reduced to an alkylamine bond), etc.
  • suitable complementary reactive moieties for the amphiphilic molecule include haloacetyl derivatives or maleimides (to form a thioether bond); and if the targeting ligand can be linked to the amphiphilic molecule through a carboxylic group, suitable reactive moieties for the amphiphilic molecule might be amines and hydrazides (to form amide or alkylamide bonds).
  • the amphiphilic compound forming the microvesicle's envelope shall thus contain a suitable reactive moiety and the targeting ligand containing the complementary functionality will be linked thereto according to known techniques, e.g. by adding it to a dispersion comprising the amphiphilic components of the microvesicle.
  • the amphiphilic compound is a lipid bearing a hydrophilic polymer, such as those previously mentioned, preferably a pegylated phospholipid.
  • the targeting ligand is linked to a suitable reactive moiety on the hydrophilic polymer.
  • the amphiphilic compound may be combined with the desired targeting ligand before preparing the microvesicle, and the so obtained combination may be used for the preparation of the microvesicle.
  • the targeting ligand may be linked to the respective amphiphilic compound during the preparation of the microvesicle.
  • the targeting ligand may also be suitably associated with the microvesicle via physical and/or electrostatic interaction.
  • a functional moiety having a high affinity and selectivity for a complementary moiety may be introduced into the amphiphilic molecule, while the complementary moiety will be linked to the targeting ligand.
  • an avidin (or streptavidin) moiety having high affinity for biotin
  • an avidin (or streptavidin) moiety having high affinity for biotin
  • a suitable targeting ligand e.g. a peptide or an antibody.
  • biotin-labelled targeting ligand will thus be associated with the avidin-labelled phospholipid of the microvesicle by means of the avidin-biotin coupling system.
  • both the phospholipid and the targeting ligand may be provided with a biotin moiety and subsequently coupled to each other by means of avidin (which is a bifunctional component capable of bridging the two biotin moieties).
  • avidin which is a bifunctional component capable of bridging the two biotin moieties.
  • van der Waal's interactions, electrostatic interactions and other association processes may associate with or bind to the targeting ligand to the amphiphilic molecules.
  • the phospholipid may be modified with a protein suitable for specific coupling to Fc domain of Immunoglubulin (Ig) such as Protein A, Protein G, Protein A/G or Protein L.
  • the targeting ligand may be a compound which is admixed with the components forming the microvesicle, to be eventually incorporated the microvesicle structure, such as, for instance, a lipopeptide as disclosed e.g. in International patent Applications WO 98/18501 or 99/55383, both herein incorporated by reference.
  • a microvesicle may first be manufactured, which comprises a compound (lipid or polymer-modified lipid) having a suitable moiety capable of interacting with a corresponding complementary moiety of a targeting ligand;
  • the desired targeting ligand is added to the microvesicle suspension, to bind to the corresponding complementary moiety on the microvesicle.
  • Suitable specific targets to which the microvesicles may be directed are, for instance, fibrin and the GPIIbllla binding receptor on activated platelets. Fibrin and platelets are in fact generally present in "thrombi", i.e. coagula which may form in the blood stream and cause a vascular obstruction.
  • thrombi i.e. coagula which may form in the blood stream and cause a vascular obstruction.
  • Suitable binding peptides are disclosed, for instance, in the above cited US 6,139,819. Further binding peptides specific for fibrin-targeting are disclosed, for instance, in International patent application WO 02/055544, which is herein incorporated by reference.
  • KDR kinase domain region
  • VEGF vascular endothelial growth factor
  • VEGF/KDR complex are disclosed, for instance, in International Patent application WO 03/74005 and WO 03/084574, both herein incorporated by reference.
  • the microvesicles according to the invention may be manufactured from the composition of the invention according to any known method in the art.
  • the manufacturing method involves the preparation of a dried powdered material comprising the composition of the invention, preferably by lyophilization (freeze drying) of an aqueous or organic suspension comprising said composition.
  • the microvesicles may then be obtained by reconstitution of the lyophilized preparation in an aqueous carrier, upon gentle agitation in the presence of a gas.
  • a composition comprising the mixture of phospholipids and fatty acids may be dispersed in an emulsion of water with a water immiscible organic solvent (e.g. branched or linear alkanes, alkenes, cyclo-alkanes, aromatic hydrocarbons, alkyl ethers, ketones, halogenated hydrocarbons, perfluorinated hydrocarbons or mixtures thereof) under agitation, preferably in admixture with a lyoprotecting agent (such as those previously listed, in particular carbohydrates, sugar alcohols, polyglycols,
  • a lyoprotecting agent such as those previously listed, in particular carbohydrates, sugar alcohols, polyglycols
  • the emulsion may be obtained by submitting the aqueous medium and the solvent in the presence of the phospholipids and fatty acids to any appropriate emulsion-generating technique known in the art, such as, for instance, sonication, shaking, high pressure homogenization, micromixing, membrane emulsification, high speed stirring or high shear mixing.
  • emulsion-generating technique known in the art, such as, for instance, sonication, shaking, high pressure homogenization, micromixing, membrane emulsification, high speed stirring or high shear mixing.
  • the so obtained microemulsion which contains microdroplets of solvent surrounded and stabilized by phospholipids and fatty acids (and optionally by other amphiphilic film-forming compounds and/or additives), is then lyophilized according to conventional techniques to obtain a lyophilized material.
  • the dried or lyophilized product is generally in the form of a powder or a cake, and may be stored (typically in a vial) in contact with the desired gas.
  • the product is readily reconstitutable in a suitable physiologically acceptable aqueous liquid carrier, which is typically injectable, to form a suspension of gas-filled microbubbles, upon gentle agitation of the suspension in the presence of a biocompatible gas.
  • suitable physiologically acceptable liquid carriers are sterile water, aqueous solutions such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or solutions of one or more tonicity adjusting substances such as salts or sugars, sugar alcohols, glycols or other non-ionic polyol materials (e.g .
  • chitosan derivatives such as carboxymethyl chitosan, trimethyl chitosan or gelifying compounds, such as carboxymethylcellulose, hydroxyethyl starch or dextran.
  • biocompatible gas gas precursor or mixture thereof may be employed to form the microvesicles of the invention (hereinafter also identified as “microvesicle- forming gas”).
  • biocompatible gas gas precursor includes any gas (or precursor thereof) which at the usual dosages of the relevant diagnostic or therapeutic application does not result in any significant adverse or toxic effect to a patient.
  • the gas may comprise, for example, air; nitrogen; oxygen; carbon dioxide;
  • a hydrogen e.g. hydrogen; nitrous oxide; nitric oxide; a noble or inert gas such as helium, argon, xenon or krypton; a low molecular weight hydrocarbon (e.g. containing up to 7 carbon atoms), for example an alkane such as methane, ethane, propane, butane, isobutane, pentane or isopentane, a cycloalkane such as cyclobutane or cyclopentane, an alkene such as propene, butene or isobutene, or an alkyne such as acetylene; an ether; a ketone; an ester; halogenated gases, preferably fluorinated gases, such as or halogenated, fluorinated or perfluorinated low molecular weight hydrocarbons (e.g.
  • halogenated hydrocarbon preferably at least some, more preferably all, of the halogen atoms in said compound are fluorine atoms.
  • Fluorinated gases are preferred, in particular perfluorinated gases.
  • Fluorinated gases include materials which contain at least one fluorine atom such as, for instance fluorinated hydrocarbons (organic compounds containing one or more carbon atoms and fluorine); sulfur hexafluoride; fluorinated, preferably perfluorinated, ketones such as perfluoroacetone; and fluorinated, preferably perfluorinated, ethers such as
  • perfluorodiethyl ether Preferred compounds are perfluorinated gases, such as SF 6 or perfluorocarbons (perfluorinated hydrocarbons), i.e. hydrocarbons where all the hydrogen atoms are replaced by fluorine atoms, which are known to form particularly stable microbubble suspensions, as disclosed, for instance, in EP 0554 213, which is herein incorporated by reference.
  • perfluorinated gases such as SF 6 or perfluorocarbons (perfluorinated hydrocarbons), i.e. hydrocarbons where all the hydrogen atoms are replaced by fluorine atoms, which are known to form particularly stable microbubble suspensions, as disclosed, for instance, in EP 0554 213, which is herein incorporated by reference.
  • perfluorocarbon includes saturated, unsaturated, and cyclic
  • perfluorocarbons are: perfluoroalkanes, such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluorobutanes (e.g. perfluoro-n-butane, optionally in admixture with other isomers such as perfluoro-isobutane), perfluoropentanes, perfluorohexanes or perfluoroheptanes; perfluoroalkenes, such as perfluoropropene, perfluorobutenes (e.g. perfluorobut-2ene) or perfluorobutadiene; perfluoroalkynes (e.g. perfluorobut-2- yne); and perfluorocycloalkanes (e.g. perfluorocyclobutane,
  • perfluoroalkanes such as perfluoromethane, perfluoroethane, perfluoropropanes, perfluoro
  • Preferred saturated perfluorocarbons include, for example, CF 4 ,
  • the mixture may comprise a conventional gas, such as nitrogen, air or carbon dioxide and a gas forming a stable microbubble suspension, such as sulfur hexafluoride or a perfluorocarbon as indicated above.
  • suitable gas mixtures may be found, for instance, in WO 94/09829, which is herein incorporated by reference.
  • the following combinations are particularly preferred : a mixture of gases (A) and (B) in which the gas (B) is a fluorinated gas, selected among those previously illustrated, including mixtures thereof, and (A) is selected from air, oxygen, nitrogen, carbon dioxide or mixtures thereof.
  • the amount of gas (B) may represent from about 0.5% to about 95% v/v of the total mixture, preferably from about 5% to 80%.
  • Particularly preferred gases are SF 6 , C 3 F 8 , C 4 F 10 or mixtures thereof, optionally in admixture with air, oxygen, nitrogen, carbon dioxide or mixtures thereof.
  • a precursor to a gaseous substance i.e. a material that is capable of being converted to a gas in vivo.
  • the gaseous precursor and the gas derived therefrom are physiologically acceptable.
  • the gaseous precursor may be pH-activated, photo-activated, temperature activated, etc.
  • certain perfluorocarbons may be used as temperature activated gaseous precursors. These perfluorocarbons, such as perfluoropentane or perfluorohexane, have a liquid/gas phase transition temperature above room
  • microvesicles according to the invention may optionally further comprise a diagnostic agent and/or a therapeutic agent, either included into the microvesicle structure or associated therewith.
  • diagnostic agent includes within its meaning any compound, composition or particle which may be used in connection with methods for imaging an internal region of a patient and/or diagnosing the presence or absence of a disease in a patient.
  • diagnostic agents incorporated into or associated with a microvesicle in a composition of the invention are any compound, composition or particle which may allow imaging enhancement in connection with diagnostic
  • diagnostic agents include, magnetic resonance imaging, X-ray, in particular computed tomography, optical imaging, nuclear imaging or molecular imaging.
  • diagnostic agents are, for instance, magnetite nanoparticles, iodinated compounds, such as Iomeprol ® , or paramagnetic ion complexes, such as hydrophobic gadolinium complexes.
  • therapeutic agent includes within its meaning any substance, composition or particle which may be used in any therapeutic application, such as in methods for the treatment (including diagnosis, prevention, alleviation, pain relief or cure) of a disease in a patient, as well as any substance which is capable of exerting or is responsible to exert a biological effect in vitro and/or in vivo.
  • Therapeutic agents thus include any compound or material capable of being used in the treatment of any pathological status in a patient (including malady, affliction, disease lesion or injury) as well as in the prevention of any such pathological status (e.g. vaccination).
  • therapeutic agents are drugs, pharmaceuticals, bioactive agents, cytotoxic agents, chemotherapy agents, radiotherapeutic agents, proteins, natural or synthetic peptides, including oligopeptides and polypeptides, vitamins, steroids and genetic material, including nucleosides, nucleotides, oligonucleotides, polynucleotides and plasmids.
  • microvesicles of the invention may also be associated with other components such as, for instance, liposomes or micelles. Said components may simply be admixed together with the microvesicles or may form an assembly through a physical and/or chemical interaction with the stabilizing envelope of the microvesicles, e.g through a covalent bound, an electrostatic or ionic interaction, Van der Waals interaction, hydrophobic or hydrophilic interaction. Examples of these associated microvesicles compositions and of the preparation thereof are disclosed, for instance, in US patent no. 6,258,378 and in International Patent Applications WO2005/063305 and
  • magnetite nanoparticles may be admixed with a charged amphiphilic material, such as those previously mentioned, in order to stabilize said particles and keep them dispersed in an aqueous solution (as disclosed for instance in US 5,545,395, herein incorporated by reference), in order to associate it with a microvesicle.
  • gadolinium complexes may be admixed with suitable micelle-forming compounds, for instance as disclosed in European Patent EP 804 251 (herein incorporated by reference), and the formed micelle may be associated with a microvesicle.
  • a therapeutic agent may be prepared as a micellar or liposomal suspension and as such being associated with a microvesicle.
  • the microvesicles according to the invention are preferably stored in dried powdered form and as such may advantageously be packaged in a two component diagnostic and/or therapeutic kit, preferably for administration by injection.
  • the kit preferably comprises a first container, containing the lyophilized composition in contact with a selected biocompatible gas and a second container, containing a physiologically acceptable aqueous carrier.
  • suitable carriers are water, typically sterile, pyrogen free water (to prevent as much as possible contamination in the intermediate lyophilized product), aqueous solutions such as saline (which may advantageously be balanced so that the final product for injection is not hypotonic), or aqueous solutions of one or more tonicity adjusting substances such as salts or sugars, sugar alcohols, glycols or other non-ionic polyol materials (e.g. glucose, sucrose, sorbitol, mannitol, glycerol, polyethylene glycols, propylene glycols and the like).
  • Said two component kit may include two separate containers or a dual-chamber container.
  • the container is preferably a conventional septum-sealed vial, wherein the vial containing the lyophilized residue is sealed with a septum through which the carrier liquid may be injected using an optionally prefilled syringe.
  • the syringe used as the container of the second component is also used then for injecting the contrast agent.
  • the dual-chamber container is preferably a dual- chamber syringe and once the lyophilisate has been reconstituted and then suitably mixed or gently shaken, the container can be used directly for injecting the contrast agent.
  • microvesicles of the present invention may be used in a variety of diagnostic and/or therapeutic techniques, including in particular Ultrasound and Magnetic
  • Diagnostic techniques include any method where the use of the gas-filled microvesicles allows enhancing the visualisation of a portion or of a part of an animal (including humans) body, including imaging for preclinical and clinical research purposes.
  • imaging techniques may be employed in ultrasound applications, for example including fundamental and harmonic B-mode imaging, pulse or phase inversion imaging and fundamental and harmonic Doppler imaging; if desired three- dimensional imaging techniques may be used.
  • Microvesicles according to the invention may typically be administered in a concentration of from about 0.01 to about 1.0 ⁇ _ of gas per kg of patient, depending e.g. on their respective composition, the tissue or organ to be imaged and/or the chosen imaging technique.
  • This general concentration range may of course vary depending on specific imaging applications, e.g . when signals can be observed at very low doses such as in colour Doppler or power pulse inversion.
  • Possible other diagnostic imaging applications include scintigraphy, light imaging, and X-ray imaging, including X-ray phase contrast imaging .
  • Therapeutic techniques include any method of treatment (as above defined) of a patient which comprises the use of gas-filled microvesicles either as such (e.g .
  • ultrasound mediated thrombolysis or in combination with a therapeutic agent (e.g . for the delivery of a bioactive compound to a selected site or tissue, such as in gene therapy or in the use as vaccine), and which is capable of exerting or responsible to exert a biological effect in vitro and/or in vivo, either by itself or upon specific activation by various physical methods (including e.g . ultrasound mediated delivery).
  • a therapeutic agent e.g . for the delivery of a bioactive compound to a selected site or tissue, such as in gene therapy or in the use as vaccine
  • Microvesicles according to the invention can typically be administered in a concentration of from about 0.01 to about 5.0 ⁇ _ of gas per kg of patient, depending e.g. from their respective composition, the type of subject under treatment, the tissue or organ to be treated and/or the therapeutic method applied .
  • - N is a number identifying whether the composition contains only a saturated fatty acid ( 1), only an unsaturated fatty acid (2) or a mixture of the two (3 or higher, where numbers higher than 3 identify different molar ratios between the two fatty acids)
  • - n is another number identifying similar relative molar amounts of the phospholipid in the different preparations.
  • DSPE-PEG2000 (2.6 mg) was mixed with 200 ⁇ of distilled water. After heating
  • micellar solution (50 °C) and mixing, a clear micellar solution is obtained and added to 20 mL of a solution of PEG 4000 at 10% (w/v) in distilled water.
  • the organic phase is added in the aqueous phase under stirring with high speed homogenizer Polytron (1 min at 9 ⁇ 00 rpm) .
  • the obtained emulsion was left one hour at 80 °C under gentle stirring and cooled down to room temperature.
  • the emulsion was diluted twice with a solution of PEG 4000 10% (w/v), and aliquoted in DIN4R vials (0.5 mL of emulsion per vial) .
  • the emulsion in the vials was lyophilized and a mixture of C 4 Fio/air (35%-65%) was introduced into the vial.
  • Vials were frozen at -50 °C for 1 h (Telstar lyophilizer), then freeze-dried at -25 °C and 0.2 mbar for 12 h. The content of the vial was then redispersed in NaCI 0.9% ( 1 mL) under gentle agitation to give the suspension of gas-filled microvesicles. The above preparation was repeated by replacing palmitic acid with similar molar amount of other saturated and unsaturated fatty acids, as indicated in the following table 1.
  • Preparation la of Example 1 was repeated by replacing the palmitic acid with the similar molar amount (about 45.5%) of a mixture containing a saturated fatty acid (about 13% by moles; 1.5 to 1.8 mg) and unsaturated fatty acid (about 32.5% by moles 3.7 to 4.4 mg), as indicated in the following table 2, admixed with 18.2 to 18.5 mg of DSPC (total to 20 mg with amount of saturated acid) and 3.0 mg of DSPE-
  • microvesicles comprising mixtures of saturated/unsaturated fatty acids compared with microvesicles comprising saturated or unsaturated fatty acids
  • the stability of the microvesicles prepared in Examples 1 and 2 was measured in the above identified Culture Medium at 37 °C over 24 hours. Two vials of each preparation were redispersed in 1 ml_ of Culture Medium and samples were characterized by Coulter Counter i) right after reconstitution and ii) after 24 hours of incubation at 37 °C under static condition. The percentage of remaining microvesicles (with respect to the initial amount measured after reconstitution) is reported in the following table 3.
  • mixtures of saturated and unsaturated fatty acids provide increased stability of microvesicles with respect to microvesicles containing the same molar amount of only the saturated or of the unsaturated fatty acid.
  • Preparation 3c of Example 2 was repeated but the molar ratio of the saturated fatty acid over the unsaturated fatty acid was varied as illustrated in table 4 (while keeping the total molar amount of saturated + unsaturated fatty acids constant at about 45.5% molar), the remainder components being DSPC (52% molar) and DSPE- PEG2000 (2.5% molar).
  • microbubbles comprising a mixture of saturated/unsaturated fatty acids of from 2.5/1 to 1/7.3 molar.
  • Preparation 3a of Example 2 was repeated but the molar ratio of the saturated fatty acid over the unsaturated fatty acid was varied as illustrated in table 5 (while keeping the total molar amount of saturated + unsaturated fatty acids constant at about 45.5% molar), the remainder components being DSPC (52% molar) and DSPE- PEG2000 (2.5% molar).
  • microbubbles comprising a mixture of saturated/unsaturated fatty acids of from 1.5/1 to 1/7.3 molar.
  • Preparation 3a of Example 2 was repeated but the molar amount of DSPC was varied with respect to the molar amount of the fatty acid mixture, as illustrated in table 6 below (the molar ratio saturated/unsaturated fatty acids being kept constant at 1:2.5).
  • the total number of moles (DSPC + palmitic acid + palmitoleic acid) for each preparation was kept constant at about 45 ⁇ -ioles.
  • Table 6 Stability of microvesicles containing different molar ratios of phospholipids vs. mixture saturated/ unsaturated fatty acids
  • Microvesicles comprising phosphatidylglycerol combined with mixture of saturated/unsaturated fatty acids
  • Preparations la, 2a (Example 1) and 3a (Example 2) were repeated but phosphatidylcholine (DSPC) was replaced by phosphatidylglycerol (DSPG) .
  • DSPC phosphatidylcholine
  • DSPG phosphatidylglycerol
  • mixtures of saturated/unsaturated fatty acids provide increased stability also to phosphatidylglycerol-containing microvesicles, when compared to compositions containing the same molar amount of only the saturated or unsaturated fatty acid .
  • Microvesicles comprising phosphatidylserine combined with mixture of
  • Example 7 was repeated but the phosphatidylglycerol (DSPG) was replaced by phosphatidylserine (DSPS) .
  • DSPG phosphatidylglycerol
  • DSPS phosphatidylserine
  • mixtures of saturated/unsatu rated fatty acids provide increased stability also to phosphatidylserine-containing microvesicies, when compared to the composition containing the same molar amount of only the saturated or unsaturated fatty acid.
  • Microvesicies comprising phosphatidylcholine combined with mixture of saturated/unsaturated fatty acids
  • Example 7 was repeated but the phosphatidylglycerol (DSPG) was replaced by phosphatidylcholine (DPPC) and the fatty acids were replaced by stearic acid and oleic acid.
  • DSPG phosphatidylglycerol
  • DPPC phosphatidylcholine
  • the stability of the obtained microvesicies was determined as above described and the results are reported in the following table 9 below.
  • mixtures of saturated/unsaturated fatty acids provide increased stability also to phosphatidylcholine-containing microvesicies, when compared to the composition containing the same molar amount of only the saturated or unsaturated fatty acid.
  • Microvesicies comprising phosphatidylcholine combined with mixture of saturated/unsaturated fatty acids
  • Example 9 was repeated but DPPC was replaced by DAPC.
  • the stability of the obtained microvesicies was determined as above described and the results are reported in the following table 10 below ⁇
  • the respective perfusion performance of the microvesicle preparations was evaluated by ultrasound imaging performed using a Siemens Seguoia 512 scanner (Siemens Medical Systems, Issaguah, WA) eguipped with a 15L8 linear transducer. Intermittent muscle imaging was performed using Cadence Pulse Seguencing (CPS) mode at low acoustic power (MI 0.25) to follow the washin/washout of microvesicies in the kidney of a rat following administration of microvesicle preparations (randomised injection).
  • CPS Cadence Pulse Seguencing
  • a guantitative analysis of microvesicies perfusion was performed using a software developed in-house (Bracco Canal SA, Geneva, Switzerland) designed to guantify contrast echo-power amplitude within areas of interest (AOI).
  • Contrast enhancement in the AOI was expressed as relative echo-power values (rms 2 ), which are proportional to the number of microvesicies in the selected AOI. Based on rms 2 values, maximum intensity (Imax, up to 30 sec post-injection) and late phase enhancement (5 and 10 min after injection) in rat kidney were evaluated . Persistency of microvesicles was determined as normalized value in percentage of the ratio between rms 2 values measured at late phase (at 5 and 10 minutes) and the Imax value.
  • microvesicles according to the invention show an increased persistency after 5 and 10 minutes from injection, with respect to microvesicles comprising the same molar amount of only the saturated fatty acid.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Acoustics & Sound (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une formulation pour la préparation de microvésicules remplies de gaz, qui comprend un phospholipide et un mélange d'acides gras saturés et insaturés. Les microvésicules remplies de gaz ayant une couche de stabilisation comprenant ladite composition présentent une stabilité accrue par rapport à des microvésicules ne contenant qu'un acide gras saturé ou insaturé.
PCT/EP2013/077337 2012-12-21 2013-12-19 Microvésicules remplies de gaz WO2014096165A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US14/653,793 US10010630B2 (en) 2012-12-21 2013-12-19 Gas-filled microvesicles
CN201380067383.8A CN105026030B (zh) 2012-12-21 2013-12-19 充气微泡
EP13821088.5A EP2934740B1 (fr) 2012-12-21 2013-12-19 Microvésicules remplies de gaz
JP2015548564A JP6313329B2 (ja) 2012-12-21 2013-12-19 ガス封入マイクロベシクル

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12199095.6 2012-12-21
EP12199095 2012-12-21

Publications (2)

Publication Number Publication Date
WO2014096165A2 true WO2014096165A2 (fr) 2014-06-26
WO2014096165A3 WO2014096165A3 (fr) 2014-10-23

Family

ID=47519925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2013/077337 WO2014096165A2 (fr) 2012-12-21 2013-12-19 Microvésicules remplies de gaz

Country Status (5)

Country Link
US (1) US10010630B2 (fr)
EP (1) EP2934740B1 (fr)
JP (1) JP6313329B2 (fr)
CN (1) CN105026030B (fr)
WO (1) WO2014096165A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102515A1 (fr) * 2014-12-22 2016-06-30 Bracco Suisse Sa Microvésicules remplies de gaz pour leur utilisation en tant que vaccin
WO2020127816A1 (fr) * 2018-12-21 2020-06-25 Bracco Suisse Sa Microvésicules remplies de gaz avec ligand
WO2021160659A1 (fr) * 2020-02-11 2021-08-19 Bracco Suisse Sa Microvésicules remplies de gaz pour utilisation thérapeutique

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102556398B1 (ko) * 2018-07-06 2023-07-17 브라코 스위스 에스.에이. 기체-충전 미세소포를 위한 동결-건조 제제

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037275A1 (fr) * 2002-10-25 2004-05-06 Wieland, Heinrich Conjugues d'acide biliaire et particules formees a l'aide de ces conjugues
WO2005024442A2 (fr) * 2003-09-05 2005-03-17 The Ohio State University Research Foundation Sonde nanoparticulaire de surveillance in vivo de l'oxygenation tissulaire
US20070041909A1 (en) * 2003-09-05 2007-02-22 The Ohio State University Research Foundation Nanoparticulate probe for in vivo monitoring of tissue oxygenation
WO2007067979A2 (fr) * 2005-12-09 2007-06-14 Bracco International B.V. Conjugués vecteur de ciblage-phospholipides
US20110268653A1 (en) * 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US20120270845A1 (en) * 2010-10-29 2012-10-25 Robin Mark Bannister Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155109A (ja) * 1984-01-23 1985-08-15 Terumo Corp リポソ−ム製剤
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (fr) 1990-04-02 1993-05-01 Sint Sa
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them
US5464696A (en) 1992-08-13 1995-11-07 Bracco International B.V. Particles for NMR imaging
JPH0748218A (ja) * 1993-08-03 1995-02-21 B N Yuki Nouhou Kenkyusho:Kk 植物の病害を防除する方法
IL116328A (en) 1994-12-16 1999-09-22 Bracco Research Sa Frozen suspension of gas microbubbles in frozen aqueous carrier for use as contrast agent in ultrasonic imaging
US6139819A (en) 1995-06-07 2000-10-31 Imarx Pharmaceutical Corp. Targeted contrast agents for diagnostic and therapeutic use
US5833948A (en) 1995-06-15 1998-11-10 Bracco Research S.A. Blood-pool imaging composition comprising micelles containing a lipophilic chelating agent and a non-ionic surfactant
EE04224B1 (et) 1996-02-19 2004-02-16 Nycomed Imaging As Gaasi mikromullide dispersioon ja selle lüofiliseeritud jääk, ultraheli kontrastaine ja selle valmistamismeetod, mikromulle eraldav maatriks ning ultraheli kontrastaine kompositsioon
WO1998018501A2 (fr) 1996-10-28 1998-05-07 Marsden, John, Christopher Ameliorations apportees a des agents diagnostiques et/ou therapeutiques ou les concernant
US20020159951A1 (en) * 1997-05-06 2002-10-31 Unger Evan C. Novel targeted compositions for diagnostic and therapeutic use
NZ506051A (en) 1998-02-09 2003-08-29 Bracco Res S Targeted delivery of biologically active media
GB9809084D0 (en) 1998-04-28 1998-06-24 Nycomed Imaging As Improvements in or relating to diagnostic/therapeutic agents
AU2002248222B2 (en) 2000-12-23 2006-04-27 Dyax Corp. Fibrin binding polypeptides useful inter alia in medical imaging processes
EP1482987B1 (fr) 2002-03-01 2014-08-13 Bracco Suisse SA Produits de synthese multivalents pour applications therapeutiques et diagnostiques
WO2003074005A2 (fr) 2002-03-01 2003-09-12 Dyax Corp. Peptides liant des recepteurs kdr et vegf/kdr et leurs utilisations en diagnostic et therapie
US9364569B2 (en) 2003-02-04 2016-06-14 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
EP1696965B1 (fr) 2003-12-22 2014-12-10 Bracco Suisse SA Systeme de microvesicule remplie de gaz a constituant actif pour l'imagerie de contraste
CA2547024C (fr) 2003-12-22 2013-12-17 Bracco Research Sa Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
EP1834635B1 (fr) * 2006-03-13 2011-07-06 Advanced in Vitro Cell Technologies, S.L. Systèmes de nanocapsules stables pour l'administration de principes actifs
KR101893423B1 (ko) * 2010-08-09 2018-08-31 브라코 스위스 에스.에이. 표적화 기체-충전 미세소포
CN103269717B (zh) * 2010-12-24 2016-08-03 博莱科瑞士股份有限公司 气体填充微囊泡用作疫苗

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004037275A1 (fr) * 2002-10-25 2004-05-06 Wieland, Heinrich Conjugues d'acide biliaire et particules formees a l'aide de ces conjugues
WO2005024442A2 (fr) * 2003-09-05 2005-03-17 The Ohio State University Research Foundation Sonde nanoparticulaire de surveillance in vivo de l'oxygenation tissulaire
US20070041909A1 (en) * 2003-09-05 2007-02-22 The Ohio State University Research Foundation Nanoparticulate probe for in vivo monitoring of tissue oxygenation
WO2007067979A2 (fr) * 2005-12-09 2007-06-14 Bracco International B.V. Conjugués vecteur de ciblage-phospholipides
US20110268653A1 (en) * 2010-04-16 2011-11-03 The Board Of Regents Of The University Of Texas System Compositions and Methods Related to Acid Stable Lipid Nanospheres
US20120270845A1 (en) * 2010-10-29 2012-10-25 Robin Mark Bannister Compositions and Methods for Treating Chronic Inflammation and Inflammatory Diseases

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 199517 Thomson Scientific, London, GB; AN 1995-126073 XP002698969, & JP H07 48218 A (BN YUKI NOHO KENKYUSHO KK) 21 February 1995 (1995-02-21) *
QIU Y ET AL: "Enhancement of skin permeation of docetaxel: A novel approach combining microneedle and elastic liposomes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 129, no. 2, 14 July 2008 (2008-07-14) , pages 144-150, XP022735035, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2008.04.019 [retrieved on 2008-05-02] *
STEVENSON K J ET AL: "The procoagulant activity of partial thromboplastin extracts: The role of phosphatidyl serine", THROMBOSIS RESEARCH, TARRYTOWN, NY, US, vol. 26, no. 5, 1 June 1982 (1982-06-01), pages 341-350, XP026453625, ISSN: 0049-3848 [retrieved on 1982-06-01] *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016102515A1 (fr) * 2014-12-22 2016-06-30 Bracco Suisse Sa Microvésicules remplies de gaz pour leur utilisation en tant que vaccin
CN107206065A (zh) * 2014-12-22 2017-09-26 博莱科瑞士股份有限公司 用作疫苗的气体填充的微囊
US10537622B2 (en) 2014-12-22 2020-01-21 Bracco Suisse S.A. Gas-filled microvesicles for use as vaccine
JP7388992B2 (ja) 2014-12-22 2023-11-29 ブラッコ・スイス・ソシエテ・アノニム ワクチンとしての使用のためのガス入りの微小胞
WO2020127816A1 (fr) * 2018-12-21 2020-06-25 Bracco Suisse Sa Microvésicules remplies de gaz avec ligand
WO2021160659A1 (fr) * 2020-02-11 2021-08-19 Bracco Suisse Sa Microvésicules remplies de gaz pour utilisation thérapeutique

Also Published As

Publication number Publication date
CN105026030B (zh) 2017-04-12
US10010630B2 (en) 2018-07-03
EP2934740B1 (fr) 2019-12-11
US20150343097A1 (en) 2015-12-03
WO2014096165A3 (fr) 2014-10-23
JP6313329B2 (ja) 2018-04-18
EP2934740A2 (fr) 2015-10-28
CN105026030A (zh) 2015-11-04
JP2016503773A (ja) 2016-02-08

Similar Documents

Publication Publication Date Title
JP4670083B2 (ja) 超音波造影剤およびその製造方法
CA2662087C (fr) Microvesicules remplies de gaz contenant des lipides modifies par polymeres
US20070128117A1 (en) Ultrasound contrast agents and process for the preparation thereof
US11071792B2 (en) Targeted gas-filled microvesicles formulation
EP1701745A1 (fr) Systeme de microvesicule remplie de gaz pour l'imagerie de contraste
WO2005063306A1 (fr) Systeme de microvesicule remplie de gaz a constituant actif pour l'imagerie de contraste
US20200360289A1 (en) Freeze-dried product and gas-filled microvesicles suspension
US10010630B2 (en) Gas-filled microvesicles

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201380067383.8

Country of ref document: CN

ENP Entry into the national phase

Ref document number: 2015548564

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 14653793

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2013821088

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13821088

Country of ref document: EP

Kind code of ref document: A2